Astaxanthin · Evidence-First Fact Sheet

Astaxanthin is a red-orange xanthophyll carotenoid from Haematococcus pluvialis microalgae and marine organisms. Meta-analysis-supported roles include skin moisture and elasticity, fatigue and exercise performance, female reproductive markers in PCOS research populations, and cardiometabolic markers including HDL-C. Multiple trials returned negative or mixed results, including no wrinkle-depth effect, no BMI or weight-regulation effect, and mixed CAD endpoints. ASXAN Group is recognized as one of the largest-scale natural astaxanthin producers globally (>15% global share). Educational reference at 6-12 mg/day with food.

Quick Summary

Astaxanthin is a red-orange xanthophyll carotenoid concentrated in the freshwater microalga Haematococcus pluvialis and in marine organisms (salmon · krill · shrimp) that consume astaxanthin-producing microalgae. With over 70 registered clinical trials and a base of seven independent systematic reviews and meta-analyses spanning skin, eye, cardiometabolic, exercise, reproductive, and inflammatory research populations, astaxanthin holds one of the deepest carotenoid evidence bases in the dietary-supplement category. Multiple meta-analyses support roles in skin moisture and elasticity, fatigue and exercise performance, female reproductive markers in PCOS research populations, and cardiometabolic markers including HDL-C. Importantly, several large trials have returned negative or mixed findings, including no significant effect on wrinkle depth in the largest pooled skin meta-analysis, no significant BMI or body-weight regulation, mixed coronary-artery-disease endpoints, and a 12-month renal-transplant trial that did not meet its primary endpoints. Astaxanthin is regulated as GRAS (United States), Novel Food (EU EFSA, ≤8 mg/day), and is permitted with a "supports skin health" claim in Brazil (ANVISA, ≥3 mg/day), one of the few authorized skin-related supplement claims globally. ASXAN Group is recognized as one of the largest-scale natural astaxanthin producers worldwide (>15% global share), with the AstaMAZ®, AstaBiotec®, and AstaNANO® ingredient families spanning standard, synthetic-biology, and nano-delivery technology routes; the group's parent-business platform is described in §7. Pregnant, lactating, and pediatric populations, individuals on anticoagulant therapy, and those managing any chronic condition should consult a healthcare provider before starting supplementation.

Overview · What is Astaxanthin?

Astaxanthin (CAS 472-61-7 · molecular formula C₄₀H₅₂O₄ · PubChem CID 5281224) is a red-orange ketocarotenoid (xanthophyll) of the carotenoid family. Its long 11-double-bond polyene backbone, capped by two terminal ionone rings each bearing a hydroxyl group at C3/C3′ and a keto group at C4/C4′, gives astaxanthin a distinctive amphipathic character: the molecule can span a lipid bilayer with its hydroxyl-keto ends anchored at both polar surfaces, an arrangement uncommon among dietary carotenoids and central to its membrane-stabilizing properties. In vitro singlet-oxygen quenching rate constants for astaxanthin (kq ≈ 2.0 × 10⁹ M⁻¹ s⁻¹) are among the highest of any naturally occurring antioxidant, approximately 100-500-fold higher than α-tocopherol (vitamin E) and several-fold higher than β-carotene on a molar basis in cell-free assays. These in vitro figures should be interpreted as indicators of chemical reactivity rather than as direct predictors of clinical magnitude in humans.

Natural sources are almost exclusively aquatic. The dominant commercial source is the freshwater microalga Haematococcus pluvialis, which accumulates astaxanthin (3-5% of dry weight under stress conditions) as a photoprotective response. Other sources include the red yeast Phaffia rhodozyma and dietary intake from wild salmon, krill, and shrimp, animals that obtain astaxanthin secondarily by feeding on astaxanthin-producing microorganisms. The pink-red coloration of wild salmon flesh is a direct dietary marker of accumulated astaxanthin. Synthetic astaxanthin (typically produced by petrochemical routes for aquaculture feed pigmentation) and natural astaxanthin (microalgae- or yeast-derived) differ in stereoisomer profile; most clinical evidence for human supplementation has been generated using Haematococcus pluvialis-derived natural astaxanthin.

After ingestion with a fat-containing meal, astaxanthin is highly lipophilic and absorption is enhanced by dietary lipids. It enters chylomicrons, is delivered to peripheral tissues through lipoprotein metabolism, and is incorporated into cell membranes throughout the body including skin, eye (retina), liver, muscle, and adipose tissue. The molecule does not interconvert to vitamin A because it lacks the requisite β-ionone ring structure on both ends.

Astaxanthin sits at the center of ASXAN Group's strategic ingredient portfolio: ASXAN is recognized, based on publicly available industry data, as one of the largest-scale natural astaxanthin producers globally (>15% share of natural astaxanthin supply), with an in-house synthetic-biology research collaboration and a multi-route ingredient platform spanning standard Haematococcus pluvialis-derived astaxanthin, synthetic-biology fermentation, and nano-delivery technology routes. The parent-business platform is described in detail in §7, and it contrasts with the fucoxanthin pillar page's marine microalgal and yeast routes. This page is part of ASXAN's evidence-first educational hub and does not constitute a purchase recommendation.

Mechanism of Action

Astaxanthin's biological activity arises from a small set of interconnected, well-characterized mechanisms. Direct human mechanistic evidence (e.g., on intracellular NRF2 translocation rates or SIRT1 protein levels) is limited relative to the rich preclinical mechanistic literature; mechanism narratives below are based on preclinical and mechanistic studies unless otherwise noted, with human signal observations referenced where available.

Direct singlet-oxygen quenching and lipid peroxidation prevention (membrane positioning). Astaxanthin's long polyene backbone and amphipathic geometry allow it to span a phospholipid bilayer, anchoring its polar hydroxyl-keto ends at both membrane surfaces while the hydrophobic core sits within the bilayer. This positioning protects membrane lipids and embedded proteins from reactive oxygen species (singlet oxygen, peroxyl and alkoxyl radicals) and from lipid peroxidation. In vitro, astaxanthin's singlet-oxygen quenching capacity is approximately 100-500-fold higher than α-tocopherol on a molar basis. This is the structural feature that most cleanly differentiates astaxanthin from lutein, β-carotene, and other dietary carotenoids, and the molecular basis for protection of low-density lipoprotein (LDL) from oxidative modification, an indirect contributor to endothelial homeostasis.

NRF2 / Keap1 pathway activation, endogenous antioxidant defense. Astaxanthin is proposed to induce a conformational change in Keap1 that releases NRF2 for nuclear translocation, where NRF2 binds antioxidant response elements (AREs) and upregulates phase II detoxification enzymes (HO-1, NQO1, GCL) and intracellular glutathione synthesis. This NRF2-mediated mechanism builds an endogenous antioxidant response, a feature shared with several carotenoids including fucoxanthin.

NF-κB signaling inhibition, anti-inflammatory effects. Astaxanthin is reported to inhibit IκB kinase (IKK) activity, blocking p65 / p50 nuclear translocation and downregulating IL-6, TNF-α, COX-2, and iNOS expression. This pathway dampens chronic low-grade inflammation across tissues and is mechanistically consistent with the inflammatory-marker and rheumatoid-arthritis-research findings discussed in §4.4 and §4.5.

PPAR-α activation, fatty-acid β-oxidation, and metabolic effects. Astaxanthin is proposed to activate PPAR-α, promoting fatty-acid β-oxidation in liver and skeletal muscle, a mechanism consistent with the fat-oxidation signals observed in endurance-exercise research (§4.3).

Mitochondrial membrane protection and emerging muscle-quality dual-pathway findings. Astaxanthin's membrane positioning extends to the mitochondrial inner membrane, where it is proposed to stabilize the electron transport chain (complexes I-III), reduce electron leak and superoxide generation, and support SIRT3-dependent deacetylation. Emerging preclinical work additionally suggests a "dual-pathway" muscle-quality contribution: FOXO1/3 → MuRF1 / Atrogin-1 inhibition (suppressing protein-degradation signals) alongside Nrf2 / PGC-1α / TFAM activation (supporting mitochondrial biogenesis). This dual-pathway model is mechanistically independent of, and may be complementary to, the mTOR / leucine-driven protein-synthesis pathway exploited by HMB and branched-chain amino acids, and is the mechanistic foundation for ASXAN's ongoing clinical research investment in muscle quality preservation (§7).

SIRT1 modulation, preliminary clinical observation. In a randomized controlled trial in adults with coronary artery disease, astaxanthin supplementation was associated with directional SIRT1 changes, though primary clinical endpoints in that trial were largely non-significant (see §4.3 and §4.6); this observation is reported as a preliminary mechanistic signal in a clinical population, not as an established human-mechanistic claim.

Taken together, astaxanthin acts not as a single-receptor pharmacologic agent but as a dietary modulator of oxidative-stress, inflammation, and mitochondrial-network homeostasis, a "network nutrient" framing that is consistent with the consistent-but-modest effect sizes observed across multiple physiological systems in human RCTs.

References: PMID 36363994 (Bjørklund 2022 mechanism review), PMID 41596351 (Malcangi 2026 SR mechanism context), PMID 37051124 (Heidari 2023 CAD SIRT1 RCT observation).

Evidence-Based Benefits

Each benefit below opens with an evidence tier label following NIH-ODS conventions: meta-analysis-supported > rct-supported > emerging > preclinical-major. Effect sizes, sample sizes, and study designs are reported as published; no values are inferred from training-data recall. Disease-related research populations are described as such; astaxanthin is not characterized as a treatment for any disease.

Inside ASXAN's Astaxanthin Evidence Base · An Orientation

Multiple benefit sections below reference findings drawn from an evidence base of more than 30 randomized controlled trials and seven independent systematic reviews and meta-analyses covering, among other research populations, adults with skin photo-aging concerns, children and adults with digital eye strain, adults with prediabetes and dyslipidemia, adults with coronary artery disease, women with polycystic ovary syndrome undergoing assisted reproduction, adults with rheumatoid arthritis, healthy older adults engaged in endurance and functional training, recreational and competitive athletes, occupational populations, and otherwise healthy adults across a broad dose range (typically 4-12 mg/day; sports and inflammatory trials extending to 20 mg/day; short-term safety trials up to 40 mg/day).

  • Independent meta-analyses across multiple physiological systems. Seven independent SRs / MAs published between 2020 and 2026 cover skin (Zhou 2021 · Ng 2021), female fertility and PCOS (Maleki-Hajiagha 2024 · Rodrigues 2024 single-arm), cardiometabolic and lipid (Xia 2020 · Leung 2022 · 2025 dose-response analyses), fatigue and exercise (Liu 2024), and overall antioxidant / anti-inflammatory / metabolic effects (Malcangi 2026 SR of 15 human studies). This multi-system pooled evidence anchors the meta-analysis-supported tier, but it is not uniform: individual sub-endpoints (wrinkle depth · BMI / weight · coronary primary endpoints) have returned non-significant pooled effects, and §4.6 reports these transparently.
  • Cluster narrative structure. Astaxanthin's clinical evidence does not yet include a single mega-trial of the scale of the VITAL trial in vitamin D3. The most rigorous way to summarize the field is via clusters of independent RCTs sharing similar protocols, doses, and endpoints. This fact sheet uses three such cluster narratives, Skin Cluster (§4.1), Eye / Visual Fatigue Cluster (§4.2), and Cardiometabolic + Exercise Cluster (§4.3), each summarizing the multi-RCT body of evidence, the consistent findings, the discrepant findings, and the methodological limitations.
  • Continuing research investment. ASXAN Group is actively investing in clinical research designed to extend the astaxanthin evidence base in areas where current evidence is preliminary, notably muscle quality preservation and reproductive health (see §7). Findings cited in §4 reflect the published evidence base as of mid-2026; ongoing trials are described in §7 and are not pre-judged in §4.

The cluster narratives below systematically describe trial interventions as "Haematococcus pluvialis-derived natural astaxanthin formulation" rather than by commercial brand name; dose, duration, sample size, primary endpoint, and reported effect sizes are preserved as published. Where a trial was industry-sponsored, this is annotated; sponsor brand names are not propagated.

Skin Health Cluster · Moisture, Elasticity, UV Resilience

Evidence Tier: meta-analysis-supported

A 2021 systematic review and meta-analysis (Zhou X et al., Nutrients) pooled 11 studies, 9 RCTs (n = 481) and 2 open-label trials, evaluating oral Haematococcus pluvialis-derived natural astaxanthin on adult skin endpoints. Across the pooled RCT body, the meta-analysis reported a statistically significant standardized mean difference of 0.49 (p < 0.001) on skin moisture and 0.46 (p < 0.05) on skin elasticity, with positive directional signals on barrier integrity and corneocyte condition; wrinkle depth, however, did not reach statistical significance at the pooled level. A 2021 systematic review (Ng QX et al., Journal of Dietary Supplements) of 11 clinical studies in adult skin populations reached substantively consistent qualitative conclusions, with the authors emphasizing high study-to-study heterogeneity.

Cluster-supporting RCTs include: a 2018 double-blind placebo-controlled trial (Ito N et al., n = 23) evaluating 4 mg/day for 9 weeks on UV-irradiated skin, which reported effect-size 0.62 on UV-induced moisture restoration and an increase in minimal erythemal dose; a 2014 double-blind placebo-controlled trial (Yoon HS et al., n = 44) evaluating 2 mg/day astaxanthin combined with 3 g/day collagen hydrolysate for 12 weeks, which reported significant facial elasticity improvement and reductions in MMP-1 and MMP-12 expression (molecular-level markers of dermal matrix turnover); and an 8-week 30-participant trial (Tominaga K et al., Acta Biochimica Polonica 2012) using 6 mg/day oral plus 2 mL/day topical, which reported reductions in crow's-feet wrinkle depth and cheek age-spot size and improvements in elasticity and corneocyte condition at week 8.

The Skin Cluster is one of the strongest evidence clusters in the astaxanthin literature in terms of statistical pooling, but two transparency notes apply. First, the pooled meta-analytic signal for wrinkle depth was not significant; the individual Tominaga 2012 trial reported wrinkle-depth improvement, but this single-RCT signal was not reproduced at the pooled level, suggesting wrinkle endpoints are sensitive to measurement protocol and study design. Astaxanthin should therefore be described as supporting skin moisture and elasticity, not as "reducing wrinkles." Second, the majority of skin RCTs were conducted in predominantly female Asian adult populations under industry-sponsored protocols, which constrains generalizability to other demographics and raises the standard publication-bias considerations.

These data support a role for Haematococcus pluvialis-derived natural astaxanthin in supporting skin moisture and elasticity in healthy adults; the wrinkle-depth qualification is reported in §4.6. They do not establish astaxanthin as a treatment for skin disease (acne, psoriasis, eczema, photoaging-related dermatologic conditions are clinical diagnoses requiring dermatologic evaluation).

References: PMID 34578794 (Zhou 2021 MA · Nutrients), PMID 32202443 (Ng 2021 SR · J Diet Suppl), PMID 29941810 (Ito 2018 UV RCT · Nutrients), PMID 24955642 (Yoon 2014 RCT · J Med Food), PMID 22428137 (Tominaga 2012 trial · Acta Biochim Pol).

Eye Health / Visual Fatigue Cluster · From Pediatric Digital Eye Strain to Adult VDT Stress

Evidence Tier: rct-supported

A 2025 multicenter double-blind randomized controlled trial (Hecht KA et al., Advances in Therapy, n = 64 children aged 10-14 years) evaluated 4 mg/day of Haematococcus pluvialis-derived natural astaxanthin for 84 days in pediatric digital eye strain (computer vision syndrome). The trial reported significant improvement on the primary visual fatigue (asthenopia) outcome and on stereopsis; visual acuity, accommodation amplitude, and refraction did not reach significance, and no serious adverse events were reported. This is one of the few astaxanthin pediatric RCTs in the modern literature.

A 2023 double-blind placebo-controlled parallel-arm RCT (published in Journal of Clinical Biochemistry and Nutrition, n = 60 healthy adults) evaluated 9 mg/day for 6 weeks against video-display-terminal (VDT) visual stress. The trial reported a statistically significant protective effect on corrected visual acuity after VDT work specifically in the ≥40-year-old subgroup; the younger (<40 years) subgroup did not show a significant effect. This age-stratified result is itself a transparency point: astaxanthin's eye-fatigue benefit appears more pronounced in middle-aged-to-older adults and in higher-VDT-exposure populations than in young healthy adults.

A 2022 prospective single-arm clinical study (Tian L et al., Frontiers in Nutrition, n = 60 patients with mild-to-moderate dry eye disease, 120 eyes) evaluated 12 mg/day for one month. The trial reported significant reductions in the Ocular Surface Disease Index (OSDI), increases in non-invasive and fluorescein tear-break-up times (NIBUT, FBUT), and improvements in corneal epithelial integrity. As a single-arm quasi-experimental design rather than a randomized placebo-controlled trial, this evidence is reported at the RCT-supported tier with the design caveat explicit. A 2020 narrative review (Giannaccare G et al., Marine Drugs) provides additional mechanistic and clinical context across retinal capillary blood flow, accommodation, and asthenopia signals.

The Eye Cluster's most reproducible signal is subjective visual fatigue / asthenopia improvement, observed in both the pediatric and the adult VDT trials. Objective accommodation, refraction, and visual acuity endpoints are more variable. Dry-eye-related tear-film stability signals come from a single non-RCT trial and require RCT replication. The cluster does not support a "vision improvement" claim in healthy young adults without elevated visual stress.

These data support astaxanthin's role in supporting visual comfort and reducing visual fatigue markers in research populations with elevated digital or VDT-related visual stress. They do not establish astaxanthin as a treatment for any ocular disease (diabetic retinopathy, age-related macular degeneration, dry eye disease, glaucoma are clinical diagnoses requiring ophthalmologic evaluation).

References: PMID 40014233 (Hecht 2025 pediatric multicenter RCT · Adv Ther), PMID 36777084 (JCBN 2023 adult VDT RCT · J Clin Biochem Nutr), PMID 35096941 (Tian 2022 dry eye prospective single-arm · Front Nutr), PMID 32370045 (Giannaccare 2020 review · Mar Drugs).

Cardiometabolic + Exercise Cluster · Lipids, Fat Oxidation, and Combined Training Interventions

Evidence Tier: rct-supported (cardiometabolic + exercise endpoints) · with meta-analytic support for HDL-C and selected lipid outcomes

Educational notice: Cardiovascular disease, coronary artery disease (ICD-10 I25), heart failure (ICD-10 I50), prediabetes, type 2 diabetes (ICD-10 E11), and metabolic syndrome (ICD-10 E88.81) are clinical diagnoses requiring medical evaluation and management. The data below evaluate astaxanthin's effects on selected lipid, glycemic, blood-pressure, body-composition, oxidative-stress, and exercise-performance markers in research populations; they do not establish astaxanthin as a treatment for any cardiovascular or metabolic disease. Individuals with diagnosed cardiovascular or metabolic conditions should not modify their care plan without consulting their cardiologist, endocrinologist, or primary care provider.

A 2020 meta-analysis of multiple RCTs (Xia W et al., Pharmacological Research) reported a significant improvement in HDL cholesterol and partial significance on systolic and diastolic blood pressure with astaxanthin supplementation in adults with cardiometabolic risk; BMI and body weight outcomes were not significant, and a 2025 lipid-profile dose-response meta-analysis (Laurindo / Rodrigues, Pharmaceuticals) further evaluated HDL / LDL / TG responses in the moderate-to-high (6-24 mg/day) dose range. A 2022 systematic review and meta-analysis of 7 RCTs (n = 321 adults at risk of metabolic syndrome, Leung LYL et al., Nutrients) reported significant LDL-C reduction and marginal total-cholesterol and SBP reductions in this population.

Cluster-supporting individual RCTs include: a 2023 double-blind placebo-controlled RCT (Ciaraldi TP et al., Diabetes, Obesity and Metabolism) in adults with prediabetes and dyslipidemia at 12 mg/day for 24 weeks, which reported significant reductions in LDL-C and total cholesterol and improvements in cardiovascular risk markers; a 2021 double-blind placebo-controlled trial (Urakaze M et al., Nutrients) in adults with prediabetes evaluating 12-week supplementation, which reported improvements in glucose metabolism and reductions in modified (oxidized) LDL with no serious adverse events; and a 2018 trial (Mashhadi NS et al., Asia Pacific Journal of Clinical Nutrition, n = 44 adults with type 2 diabetes) at 8 mg/day for 8 weeks, which reported increases in serum adiponectin, reductions in visceral fat, and reductions in triglycerides, VLDL, and systolic blood pressure.

The exercise-and-training arm of this cluster is among the densest in the astaxanthin literature: a 2024 meta-analysis of 11 RCTs (Liu C et al., Biological Research for Nursing, n = 346) reported significant improvements in fatigue and motor function, with a directional trend for cognition; doses ≥20 mg/day and durations ≥12 weeks were associated with stronger effects. A 2021 double-blind crossover RCT (Brown DR et al., Journal of Science and Medicine in Sport, n = 12 recreational cyclists) at 12 mg/day for 7 days reported a 1.2% improvement in 40 km cycling time-trial performance (p = 0.029) and an increase of approximately 0.09 g/min in whole-body fat oxidation (p = 0.044). A 2021 double-blind RCT (Liu SZ et al., Physiological Reports, n = 42 elderly adults aged 65-82) over 3 months of aerobic training reported enhanced metabolic adaptation including increased fat oxidation and improved muscle endurance, with the effect more pronounced in older male participants. A 2018 RCT (Liu SZ et al., Journal of Cachexia, Sarcopenia and Muscle, n = 42 elderly aged 65-82, 4 months) combined a 12 mg/day astaxanthin + 10 mg/day tocotrienol + 6 mg/day zinc formulation with functional training and reported significant improvements in walking distance, endurance, muscle strength, and muscle cross-sectional area versus training alone. A 2023 four-arm double-blind RCT (Saeidi A et al., Nutrients, n = 68 males with obesity, 12 weeks, 20 mg/day) combined high-intensity functional training with astaxanthin and reported reductions in adipokines and cardiovascular risk factors with the most pronounced changes in the combined training-plus-supplement arm.

Three transparency notes anchor the cardiometabolic + exercise cluster:

  • CAD signal is partially negative. A 2023 double-blind placebo-controlled RCT (Heidari M et al., Frontiers in Nutrition, n = 50 patients with coronary artery disease at 12 mg/day for 8 weeks) reported a significant reduction in total cholesterol but non-significant changes in body composition, glycemic parameters, TNF-α, and SIRT1. Astaxanthin should not be characterized as a CAD treatment, and this mixed-endpoint pattern is reported transparently rather than cherry-picked.
  • Occupational tactical population mixed. A 2024 crossover RCT in male firefighters (Gonzalez DE et al., Journal of the International Society of Sports Nutrition, n = 15, 12 mg/day for 4 weeks) reported non-significant fasting oxidative, blood lipid, and fire-ground task outcomes; only ventilatory anaerobic threshold improved. The small sample size and crossover design limit interpretation.
  • Heart failure data are protocol-stage. A 2024 publication (Mohammadi SG et al., Trials, n = 80 with heart failure, 20 mg/day for 8 weeks) describes a trial protocol with an extensive endpoint panel (inflammatory markers, oxidative stress, lipid profile, uric acid, blood pressure, endothelial function, QoL); completed primary-endpoint analyses await full publication.

These data support astaxanthin's role in supporting healthy lipid markers (particularly HDL-C), insulin-sensitivity and glycemic markers in research populations with elevated baseline values, fat oxidation during endurance exercise, and combined training-and-supplement interventions in older and metabolically vulnerable populations. They do not support BMI or weight-regulation claims, do not establish astaxanthin as a treatment for any cardiovascular or metabolic disease, and explicitly include the CAD, firefighter, and HF caveats above. Adults with established cardiovascular conditions or on cardiometabolic medications should consult their treating clinician.

References: PMID 32755613 (Xia 2020 MA · Pharmacol Res), Leung 2022 (Nutrients · PMC9148008), Laurindo / Rodrigues 2025 (Pharmaceuticals · PMC12389351), PMID 36999233 (Ciaraldi 2023 RCT · Diabetes Obes Metab), PMID 34959932 (Urakaze 2021 RCT · Nutrients), PMID 29384321 (Mashhadi 2018 T2DM RCT · APJCN), PMID 37051124 (Heidari 2023 CAD RCT, partial negative · Front Nutr), PMID 39090754 (Mohammadi 2024 HF protocol · Trials), PMID 38243785 (Liu 2024 fatigue MA · Biol Res Nurs), PMID 32660833 (Brown 2021 cycling crossover · J Sci Med Sport), PMID 34110707 (Liu 2021 elderly aerobic · Physiol Rep), PMID 30259703 (Liu 2018 sarcopenia · J Cachexia Sarcopenia Muscle), PMID 39568140 (Gonzalez 2024 firefighter, mixed · J Int Soc Sports Nutr), PMID 36678157 (Saeidi 2023 HIFT obesity · Nutrients).

Reproductive Health Markers in PCOS and Endometriosis Research Populations

Evidence Tier: rct-supported (with single-arm meta-analytic support for PCOS)

Educational notice: Polycystic ovary syndrome (PCOS, ICD-10 E28.2), endometriosis (ICD-10 N80), and infertility (ICD-10 N97 / N46) are clinical diagnoses requiring evaluation and management by a reproductive endocrinologist, gynecologist, or other qualified specialist. The data below evaluate astaxanthin's effects on selected oxidative-stress, inflammatory, lipid, insulin-resistance, and reproductive-outcome markers in research populations with diagnosed PCOS or endometriosis, including women undergoing assisted reproductive technology (ART). These studies do not establish astaxanthin as a treatment for PCOS, endometriosis, infertility, or any reproductive condition. Individuals planning or undergoing fertility treatment should consult their reproductive endocrinologist before adding any supplement to their care plan; supplements may interact with ART protocols and should not be self-managed.

A 2024 systematic review and single-arm meta-analysis (Rodrigues VD et al., Naunyn-Schmiedeberg's Archives of Pharmacology) of 4 RCTs in women with PCOS reported significant improvement in follicular-fluid total antioxidant capacity (TAC) and modest improvements in oocyte quality and high-quality embryo yield, with fertilization rates non-significantly different from comparators. A 2024 systematic review and meta-analysis (Maleki-Hajiagha A et al., Journal of Ovarian Research) of clinical and animal studies on female fertility outcomes reported a pooled oocyte-maturation-rate mean difference of +8.40 (95% CI 4.57 to 12.23, I² = 0%) and a pooled follicular-fluid TAC mean difference of +0.04 (95% CI 0.02 to 0.06), the strongest pooled evidence currently available for astaxanthin in the female reproductive-marker domain.

Cluster-supporting RCTs include: a 2024 triple-blind double-blind RCT (Fereidouni F et al., Inflammopharmacology) in women with PCOS undergoing assisted reproductive technology at 6 mg/day for 8 weeks of pretreatment, which reported a significantly higher proportion of high-quality embryos and reductions in pro-inflammatory cytokines versus placebo; a 2024 triple-blind RCT (Jabarpour M et al., Phytotherapy Research, n = 58 PCOS) at 12 mg/day for 8 weeks, which reported increases in HDL-C (37.61 → 41.80 mg/dL, p = 0.003) and reductions in LDL-C (91.27 → 82.52 mg/dL, p = 0.013) alongside improvements in oxidative-stress markers; a 2024 RCT in poor ovarian responders (Shafie A et al., Journal of Ovarian Research) which reported alleviation of oxidative stress, inflammation, and apoptosis markers alongside improved ART outcomes; and a 2023 triple-blind placebo-controlled RCT (Rostami S et al., Frontiers in Endocrinology, n = 50 endometriosis patients undergoing assisted reproduction, 6 mg/day for 12 weeks) which reported reductions in serum and follicular-fluid IL-1β / IL-6 / TNF-α, increases in SOD and TAC, and improvements in reproductive outcomes.

These data support astaxanthin's role in supporting reproductive markers, including oxidative-stress, inflammatory, lipid, and oocyte-quality-related parameters, in research populations of women with PCOS or endometriosis, including those undergoing assisted reproductive technology, when used as an adjunctive nutritional intervention. They do not establish a treatment effect on PCOS, endometriosis, or infertility, do not characterize astaxanthin as a fertility treatment or as a substitute for ART, and do not establish safety or efficacy in self-managed (non-supervised) reproductive-health contexts. Consult your reproductive endocrinologist or qualified specialist before use in the reproductive setting.

References: PMID 39127677 (Maleki-Hajiagha 2024 fertility MA · J Ovarian Res), PMID 39269488 (Rodrigues 2024 PCOS single-arm MA · Naunyn-Schmiedeberg's Arch Pharmacol), PMID 38916710 (Fereidouni 2024 PCOS ART RCT · Inflammopharmacology), PMID 37874168 (Jabarpour 2024 PCOS lipid RCT · Phytother Res), PMID 39482765 (Shafie 2024 poor ovarian responder RCT · J Ovarian Res), PMID 37020589 (Rostami 2023 endometriosis ART RCT · Front Endocrinol).

Inflammatory Markers in Rheumatoid Arthritis and Adjunctive-Therapy Research Contexts

Evidence Tier: rct-supported

Educational notice: Rheumatoid arthritis (ICD-10 M05 / M06) and other systemic autoimmune diseases are clinical diagnoses that require management by a rheumatologist or other qualified specialist. The data below evaluate astaxanthin's effects on selected disease-activity and inflammatory-marker outcomes in research populations with diagnosed rheumatoid arthritis. These studies do not establish astaxanthin as a treatment, cure, or substitute for evidence-based disease-modifying antirheumatic drug (DMARD), biologic, or other rheumatologic therapy. Individuals with diagnosed RA or any autoimmune condition should not modify their treatment regimen without consulting their rheumatologist or treating specialist.

A 2025 double-blind placebo-controlled RCT (Grigorian A et al., Food & Function) in adults with rheumatoid arthritis evaluated 20 mg/day for 8 weeks. The trial reported significant improvements in DAS-28 disease-activity scores, C-reactive protein, and quality-of-life measures in the active arm versus placebo. As a single RCT in a disease-research population, this evidence is reported at the RCT-supported tier rather than the meta-analytic tier; replication in independent RA populations would strengthen the evidence base.

A 2010 double-blind placebo-controlled RCT (Park JS et al., Nutrition & Metabolism (London)) in healthy young women across an 8-week 2-8 mg/day dose range reported improvements in lymphocyte proliferation and natural-killer cell activity at weeks 4 and 8, with an improved tuberculin-test response at week 8, providing supporting evidence for astaxanthin's effects on immune-response markers in a non-disease research population.

A 2025 double-blind placebo-controlled RCT (Youssef FM et al., Frontiers in Pharmacology, PMC12367760) evaluated astaxanthin (12 mg/day for 7 days) as an adjunctive therapy alongside standard antibiotics in adults hospitalized with community-acquired pneumonia (ICD-10 J18). The trial reported reductions in IL-6 and TNF-α, an increase in IL-10, and signal on SOFA / APACHE-II severity scores and length of stay. This is explicitly an adjunctive (not stand-alone) supplement evaluation in a hospitalized disease population; the trial does not support astaxanthin as a substitute for antibiotic therapy or as a standalone respiratory-infection treatment, and is reported here only to contextualize the inflammatory-marker evidence base. A 2026 systematic review of 15 human studies published 2020-2025 (Malcangi G et al., International Journal of Molecular Sciences) provides additional context on the consistency of inflammatory-marker findings (IL-6, TNF-α, TGF-β1 reductions; SOD and TAC increases) across the broader astaxanthin clinical literature.

These data support astaxanthin's role in supporting inflammatory-marker management in research populations with rheumatoid arthritis and in research contexts where adjunctive nutritional intervention has been evaluated. They do not establish astaxanthin as a treatment for rheumatoid arthritis or any inflammatory disease, do not substitute for DMARD, biologic, or antibiotic therapy, and should not be used by individuals with diagnosed inflammatory or infectious disease without consulting their treating specialist.

References: PMID 40569081 (Grigorian 2025 RA RCT · Food Funct), PMID 20205737 (Park 2010 immune-response RCT · Nutr Metab (Lond)), Youssef 2025 (CAP adjunctive RCT · Front Pharmacol · PMC12367760 · DOI 10.3389/fphar.2025.1621308), PMID 41596351 (Malcangi 2026 SR · Int J Mol Sci).

Dosage

Most clinical evidence for astaxanthin uses oral doses in the range of 4-12 mg/day, taken with a fat-containing meal to support absorption (astaxanthin is highly lipophilic and intrinsic bioavailability is enhanced by dietary lipids). Higher-dose sports and inflammatory-marker trials extend to 20 mg/day; short-term safety trials have evaluated up to 40 mg/day.

Typical validated dose ranges by use case, based on published RCT and meta-analytic data:

Direction Validated dose Typical onset Source
Skin moisture and elasticity 3-6 mg/day 6-16 weeks Zhou 2021 MA · Ito 2018 · Yoon 2014 · Tominaga 2012
UV-related skin resilience 4 mg/day ≥9 weeks Ito 2018
Visual fatigue / asthenopia (digital eye strain) 4-12 mg/day 4-12 weeks Hecht 2025 (pediatric) · JCBN 2023 (adult VDT ≥40 y) · Tian 2022 (dry-eye single-arm)
Cardiometabolic / lipid markers 6-12 mg/day 8-24 weeks Ciaraldi 2023 · Xia 2020 MA · Leung 2022 MA
Glucose metabolism markers (prediabetes / T2DM research) 8-12 mg/day 8-12 weeks Urakaze 2021 · Mashhadi 2018
Reproductive markers in PCOS / endometriosis research populations 6-12 mg/day 8-12 weeks (often during ART pretreatment) Fereidouni 2024 · Jabarpour 2024 · Maleki-Hajiagha 2024 MA
Fatigue, motor function, and exercise performance 4-12 mg/day (≥20 mg/day for stronger signals) 4-12 weeks Liu 2024 MA · Brown 2021 · Saeidi 2023
Combined training + sarcopenia / mobility (older adults) 12 mg/day (+ tocotrienol + zinc, with functional training) 4 months Liu 2018 (J Cachexia Sarcopenia Muscle)
Inflammatory-marker support in RA research populations 20 mg/day 8 weeks Grigorian 2025

Daily dosing with food is the standard protocol in the cited RCT literature; intermittent or bolus regimens have not been systematically evaluated for astaxanthin and are not supported by the current evidence base.

Regulatory framework, four jurisdictions.

Market Regulatory status Dose ceiling Authorized health claims
US FDA GRAS (GRN 294 / 580 / 700, Haematococcus pluvialis-derived) · New Dietary Ingredient (NDI) notifications support short-term use up to 24 mg/day NDI-supported 4-12 mg/day for ongoing use; up to 24 mg/day short-term Structure / function claims permitted with appropriate disclaimer language under DSHEA
EU EFSA Novel Food authorized for Haematococcus pluvialis-derived astaxanthin in food supplements ≤8 mg/day (EFSA 2014/2020 reassessment · ADI 0.2 mg/kg bw/day) No EFSA-authorized health claims (2009 / 2011 Article 13 / 14 submissions were not authorized)
CN NMPA New Food Raw Material (Ministry of Health 2010 Notice No. 17) · Health-food category (>30 registered products) ≤0.8 g/day Haematococcus algal powder (or ≤240 mg/day algal oil), calculated as free astaxanthin equivalent NMPA-approved health-food functions include immune support, antioxidant support, alleviating visual fatigue, and lipid management (product-level approval required)
BR ANVISA RDC 243/2018 + IN 28/2018 + IN 275/2024 framework ≤6 mg/day for adults aged ≥19 (2026-04-19 ANVISA framework; older "≤12 mg" references are outdated) Permitted "supports skin health" claim ("ajuda a manter a saúde da pele") at ≥3 mg/day, the only jurisdiction with an authorized skin claim for astaxanthin in the four-market matrix

Individual response varies. Consult a healthcare provider for personalized dosage assessment, particularly if you are pregnant or lactating, take anticoagulant or other prescription medication, or are managing any chronic condition.

Safety and Drug Interactions

Astaxanthin has an excellent safety profile across the doses and durations evaluated in human RCTs. EFSA's 2014 and 2020 reassessments established a no-observed-adverse-effect level (NOAEL) of 800 mg/kg body weight/day in a 90-day subchronic rat toxicity study and an acceptable daily intake (ADI) of 0.2 mg/kg body weight/day (raised in 2019). The Brazilian ANVISA framework sets an adult daily ceiling of 6 mg/day; EU EFSA sets ≤8 mg/day for supplements; US FDA NDI notifications support 4-12 mg/day ongoing and up to 24 mg/day short-term.

Highest-dose human evidence. A 2008 double-blind placebo-controlled three-arm RCT (Kupcinskas L et al., Phytomedicine, n = 132, placebo / 16 mg/day / 40 mg/day for 4 weeks in adults with functional dyspepsia) reported no significant adverse events at 40 mg/day. A 2016 12-month trial in renal-transplant recipients (Coombes JS et al., XANTHIN trial, 12 mg/day for 12 months) demonstrated good tolerability over an extended duration, though the trial's efficacy primary endpoints were not met (see §4.6). A 2011 trial in healthy smokers (Kim JH et al., J Med Food) at 5, 20, and 40 mg/day for 3 weeks demonstrated tolerability across the dose range.

Adverse events. The most commonly observed safety findings are limited to occasional mild, reversible orange-coloration of feces or skin (a reversible carotenoid-accumulation phenomenon that resolves on discontinuation). Serious adverse events have not been characteristic of the clinical literature at the doses studied.

Drug interactions. No clinically significant drug interactions are currently established. Theoretical additive effects with anticoagulant medication (warfarin, direct oral anticoagulants) have been raised based on astaxanthin's antioxidant and membrane-stabilizing properties; head-to-head clinical interaction data are limited, and individuals on anticoagulant therapy should consult their prescribing clinician before adding astaxanthin. The cardiometabolic, lipid, blood-pressure, and glycemic signals reported in §4.3 also suggest that individuals on antihypertensive or antihyperglycemic medications should consult their prescribing clinician before adding astaxanthin.

Special populations.

References: Kupcinskas 2008 (PMID 18467083 · 40 mg/day safety RCT), Kim 2011 (PMID 21883001 · smokers dose-range), Coombes 2016 (PMID 26675778 · XANTHIN renal-transplant 12-month tolerability), EFSA Scientific Opinion 2014 / 2020 (Novel Food reassessment).

Behind the Science · ASXAN's Astaxanthin Platform

This section describes ASXAN's research and supply-chain platform for astaxanthin. asxan.ai is an educational hub and does not promote any specific product or investment opportunity; this section is included to contextualize the parent-business technical capabilities that underpin ASXAN's ingredient-supply leadership and ongoing clinical research investment.

Astaxanthin is more than a single ingredient; it is a research program. Based on publicly available industry data, ASXAN Group is recognized as one of the largest-scale natural astaxanthin producers globally, supplying the ingredient at scale across multiple consumer and B2B channels while simultaneously investing in next-generation biosynthesis, advanced delivery formats, and clinical research. The platform spans five elements that together define ASXAN's parent-business positioning in the category.

Global natural-astaxanthin supply leadership. ASXAN holds an estimated greater-than-15% share of global natural astaxanthin supply, with production rooted in Haematococcus pluvialis photoautotrophic cultivation and downstream processing infrastructure positioned across the four major regulatory jurisdictions described in §5 (US FDA GRAS, EU EFSA Novel Food, CN NMPA New Food Raw Material, BR ANVISA approved). This regulatory breadth, the four-market compliance footprint, distinguishes ASXAN among large-scale natural astaxanthin suppliers and is a structural input to the group's ability to support multi-jurisdiction product programs. This carotenoid platform should be read alongside ASXAN's fucoxanthin platform, which uses distinct marine microalgal and yeast routes under the same evidence-first educational framing.

Three complementary ingredient routes, AstaMAZ®, AstaBiotec®, AstaNANO®. ASXAN's ingredient platform is organized across three orthogonal technology routes: AstaMAZ® is the standard Haematococcus pluvialis-derived natural astaxanthin ingredient family, the workhorse of the four-market compliance portfolio and the route most directly tied to the published RCT evidence base described in §4. AstaBiotec® is the synthetic-biology / microbial-fermentation route, designed for long-term scalability and cost trajectory improvements as fermentation processes mature. AstaNANO® is the nano-emulsified / self-emulsifying delivery route, designed to address the lipophilic-absorption bottleneck that limits standard astaxanthin bioavailability and to support application formats, beverages, cosmetics, and advanced delivery systems, where standard powder or oleoresin formats are not suitable. The three routes together provide a "consumer standard / technology frontier / formulation breadth" coverage matrix; ASXAN does not claim head-to-head clinical superiority of any one route, and route-level clinical evidence remains an active research domain.

Synthetic-biology research collaboration. ASXAN is exploring next-generation astaxanthin biosynthesis pathways through a research collaboration with a leading European synthetic-biology institution. The collaboration includes work on de novo biosynthetic pathway construction in microbial chassis (a research direction relevant to long-term cost-of-production trajectories) and engages broader capabilities in AI-assisted enzyme and non-natural protein design. The collaboration is positioned within an integrated research framework that combines synthetic-biology pathway engineering, advanced cellular delivery research, and ingredient commercialization expertise. ASXAN does not currently market synthetic-biology-derived astaxanthin as a finished commercial product; this work is in the research-and-development stage and is described here for educational context rather than as a current-availability claim.

Million-dollar clinical research investment, muscle quality preservation and reproductive health. In April 2026, ASXAN Group committed approximately one million US dollars in dedicated clinical-research funding to two strategic astaxanthin research directions. The first direction, muscle quality preservation in older adults, extends the preliminary signals discussed in §4.3 (Liu 2018 sarcopenia RCT; Liu 2021 aerobic-training RCT in elderly) and is designed around the dual-pathway mechanistic framework described in §3 (FOXO1/3 → MuRF1 / Atrogin-1 inhibition + Nrf2 / PGC-1α / TFAM activation), a mechanism that is independent of and potentially complementary to the mTOR / leucine-driven pathway of HMB and branched-chain amino acids. The second direction, female reproductive health in PCOS and adjacent populations, extends the cluster discussed in §4.4 (Maleki-Hajiagha 2024 MA; Fereidouni / Jabarpour / Shafie / Rostami trials). The program targets at least two peer-reviewed journal publications and two to four invention patents over its multi-year horizon and is described here for educational context, to indicate the parent-business research investment underpinning the astaxanthin evidence-base trajectory, rather than as a current clinical claim.

Supply-chain integration with established biomanufacturing partners. ASXAN's supply-chain strategy includes long-term partnerships with leading biomanufacturing organizations in the biopharmaceutical and biotechnology sectors. Current planning includes exploration of strategic integration with established biomanufacturing infrastructure, including large-scale fermentation capacity relevant to next-generation astaxanthin production routes and to ASXAN's broader nutritional-ingredient portfolio. This integration work is at the planning and exploratory stage. Specific partner identities, transaction structures, and timing remain subject to ongoing commercial discussions and are not described in this educational page.

This section describes ASXAN's research and supply-chain platform; asxan.ai provides educational content only and does not promote any specific product or investment opportunity.

References

All PMIDs verified by cross-source PubMed search on 2026-05-23 by the upstream Scita evidence document. Effect sizes are reported as published. Trial interventions are described systematically as "Haematococcus pluvialis-derived natural astaxanthin formulation" or equivalent generic terminology; commercial brand names are not propagated, and industry-sponsorship disclosure is annotated where relevant.

Skin Health (§4.1)

  1. PMID 34578794 · Zhou X et al. (2021) · "Systematic Review and Meta-Analysis on the Effects of Astaxanthin on Human Skin Ageing" · Nutrients · 11-study SR/MA · n = 481 RCT subset · moisture SMD 0.49 (p < 0.001) · elasticity SMD 0.46 (p < 0.05) · wrinkle depth NS · industry-sponsored trials in the pool
  2. PMID 32202443 · Ng QX et al. (2021) · "Effects of Astaxanthin Supplementation on Skin Health: A Systematic Review of Clinical Studies" · Journal of Dietary Supplements
  3. PMID 29941810 · Ito N, Seki S, Ueda F (2018) · "The Protective Role of Astaxanthin for UV-Induced Skin Deterioration in Healthy People, A Randomized, Double-Blind, Placebo-Controlled Trial" · Nutrients · DB-RCT n = 23 · 4 mg/day × 9 weeks
  4. PMID 24955642 · Yoon HS et al. (2014) · "Supplementing with dietary astaxanthin combined with collagen hydrolysate improves facial elasticity and decreases matrix metalloproteinase-1 and -12 expression: a comparative study with placebo" · Journal of Medicinal Food · DB-RCT n = 44 × 12 weeks
  5. PMID 22428137 · Tominaga K et al. (2012) · "Cosmetic benefits of astaxanthin on humans subjects" · Acta Biochimica Polonica · n = 30 female × 8 weeks (oral + topical combination)

Eye Health / Visual Fatigue (§4.2)

  1. PMID 40014233 · Hecht KA, Marwah M, Wood V et al. (2025) · pediatric digital eye strain (computer vision syndrome) multicenter DB-RCT n = 64 children 10-14 y · 4 mg/day × 84 d · Advances in Therapy · industry-sponsored
  2. PMID 35096941 · Tian L et al. (2022) · "Benefits and Safety of Astaxanthin in the Treatment of Mild-To-Moderate Dry Eye Disease" · Frontiers in Nutrition · prospective single-arm n = 60 (120 eyes) · 12 mg/day × 1 month
  3. PMID 36777084 · (per Journal of Clinical Biochemistry and Nutrition 2023) · "Effects of diet containing astaxanthin on visual function in healthy individuals: a randomized, double-blind, placebo-controlled, parallel study" · n = 60 healthy adults × 6 wk · 9 mg/day · <40 y subgroup NS
  4. PMID 32370045 · Giannaccare G, Pellegrini M, Senni C et al. (2020) · "Clinical Applications of Astaxanthin in the Treatment of Ocular Diseases: Emerging Insights" · Marine Drugs · narrative review

Cardiometabolic + Lipid + Glycemic (§4.3 component)

  1. PMID 32755613 · Xia W et al. (2020) · "The effects of astaxanthin supplementation on obesity, blood pressure, CRP, glycemic biomarkers, and lipid profile: A meta-analysis of randomized controlled trials" · Pharmacological Research · HDL-C ↑ significant · BMI / body weight NS
  2. PMID 36999233 · Ciaraldi TP et al. (2023) · "Astaxanthin, a Natural Antioxidant, Lowers Cholesterol and Markers of Cardiovascular Risk in Individuals with Prediabetes and Dyslipidemia" · Diabetes, Obesity and Metabolism · DB-PC RCT · 12 mg/day × 24 wk
  3. PMC12389351 · Laurindo LF / Rodrigues VD (2025) · "Assessing the Effects of Moderate to High Dosage of Astaxanthin Supplementation on Lipid Profile Parameters, A Systematic Review and Meta-Analysis of Randomized Controlled Studies" · Pharmaceuticals · DOI 10.3390/ph18081097
  4. PMID 34959932 · Urakaze M et al. (2021) · "The Beneficial Effects of Astaxanthin on Glucose Metabolism and Modified Low-Density Lipoprotein in Healthy Volunteers and Subjects with Prediabetes" · Nutrients
  5. PMID 29384321 · Mashhadi NS et al. (2018) · "Astaxanthin improves glucose metabolism and reduces blood pressure in patients with type 2 diabetes mellitus" · Asia Pacific Journal of Clinical Nutrition · DB-PC RCT n = 44 · 8 mg/day × 8 wk
  6. PMC9148008 · Leung LYL et al. (2022) · "Astaxanthin Influence on Health Outcomes of Adults at Risk of Metabolic Syndrome: A Systematic Review and Meta-Analysis" · Nutrients · DOI 10.3390/nu14102050 · 7 RCTs n = 321
  7. PMID 37051124 · Heidari M, Saedisomeolia A et al. (2023) · CAD RCT n = 50 · 12 mg/day × 8 wk · Frontiers in Nutrition · TC significant · body composition / glycemic / TNF-α / SIRT1 NS
  8. PMID 39090754 · Mohammadi SG et al. (2024) · heart-failure trial protocol + early outcomes · DB-PC RCT n = 80 · 20 mg/day × 8 wk · Trials · primary endpoint full data pending

Exercise / Sports / Recovery (§4.3 component)

  1. PMID 38243785 · Liu C, Dong X, Jia J et al. (2024) · fatigue + motor function + cognition MA of 11 RCTs n = 346 · Biological Research for Nursing · cognition NS at pooled level
  2. PMID 32660833 · Brown DR et al. (2021) · 40 km cycling time-trial DB-crossover n = 12 recreational cyclists · 12 mg/day × 7 d · Journal of Science and Medicine in Sport
  3. PMID 34110707 · Liu SZ et al. (2021) · elderly aerobic training DB-RCT n = 42 (65-82 y) · 3 months · Physiological Reports
  4. PMID 30259703 · Liu SZ, Ali AS, Campbell MD et al. (2018) · sarcopenia + functional training DB-PC RCT n = 42 elderly (65-82 y) · 12 mg/day + tocotrienol + zinc + functional training × 4 months · Journal of Cachexia, Sarcopenia and Muscle
  5. PMID 39568140 · Gonzalez DE, Dickerson BL, Johnson SE et al. (2024) · firefighter cardiometabolic + tactical performance DB-PC crossover n = 15 male firefighters · 12 mg/day × 4 wk · Journal of the International Society of Sports Nutrition · multi-endpoint NS · industry-sponsored
  6. PMID 36678157 · Saeidi A et al. (2023) · HIFT + astaxanthin DB-RCT n = 68 obese males · 20 mg/day × 12 wk · 4-arm design · Nutrients

Reproductive Health (PCOS + Endometriosis + ART) (§4.4)

  1. PMID 39127677 · Maleki-Hajiagha A, Shafie A, Maajani K et al. (2024) · "Effect of astaxanthin supplementation on female fertility and reproductive outcomes: a systematic review and meta-analysis of clinical and animal studies" · Journal of Ovarian Research · oocyte maturation MD +8.40 · follicular fluid TAC MD +0.04
  2. PMID 39269488 · Rodrigues VD et al. (2024) · PCOS oxidative stress + reproductive single-arm MA of 4 RCTs · Naunyn-Schmiedeberg's Archives of Pharmacology
  3. PMID 38916710 · Fereidouni F et al. (2024) · PCOS ART pretreatment triple-blind DB-RCT · 6 mg/day × 8 wk · Inflammopharmacology
  4. PMID 37874168 · Jabarpour M, Aleyasin A, Shabani Nashtaei M et al. (2024) · PCOS lipid + insulin resistance + BP + oxidative stress triple-blind RCT n = 58 · 12 mg/day × 8 wk · Phytotherapy Research
  5. PMID 39482765 · Shafie A, Aleyasin A, Saffari M et al. (2024) · poor ovarian responders ART RCT · Journal of Ovarian Research
  6. PMID 37020589 · Rostami S, Alyasin A, Saedi M et al. (2023) · endometriosis ART triple-blind PC-RCT n = 50 · 6 mg/day × 12 wk · Frontiers in Endocrinology

Inflammatory Markers / RA / Immune / Adjunctive (§4.5)

  1. PMID 40569081 · Grigorian A et al. (2025) · RA DB-RCT · 20 mg/day × 8 wk · DAS-28 + CRP + QoL · Food & Function
  2. PMID 20205737 · Park JS et al. (2010) · healthy young women immune response DB-PC RCT · 2-8 mg/day × 8 wk · Nutrition & Metabolism (London)
  3. PMC12367760 · Youssef FM, Ateyya H, Samy AEH, Elmokadem EM (2025) · community-acquired pneumonia adjunctive DB-PC RCT · 12 mg/day × 7 d + standard antibiotics · Frontiers in Pharmacology · DOI 10.3389/fphar.2025.1621308 · adjunctive (not stand-alone), does not substitute for antibiotic therapy
  4. PMID 41596351 · Malcangi G, Inchingolo AM, Casamassima L et al. (2026) · "The Role of Astaxanthin as an Antioxidant and Anti-Inflammatory Agent in Human Health: A Systematic Review" · International Journal of Molecular Sciences · SR of 15 human studies 2020-2025

Safety / Smokers / Mechanism Review (§3, §6, §4.6)

  1. PMID 18467083 · Kupcinskas L et al. (2008) · 40 mg/day × 4 wk safety DB-PC RCT n = 132 (functional dyspepsia) · Phytomedicine
  2. PMID 21883001 · Kim JH, Chang MJ, Choi HD et al. (2011) · healthy smokers oxidative stress RCT · 5 / 20 / 40 mg/day × 3 wk · Journal of Medicinal Food
  3. PMID 36363994 · Bjørklund G et al. (2022) · nutraceutical mechanism review · Molecules

Negative-Findings References (cited in §4.6 for transparency)

  1. PMID 33885235 · Kumalic SI et al. (2020) · male fertility RCT n = 72 · studied semen parameters NS, cited as negative-evidence reference; not listed as a §4 benefit
  2. PMID 26675778 · Coombes JS et al. (2016) · XANTHIN trial in renal-transplant recipients · 12 mg/day × 12 months · American Journal of Kidney Diseases · arterial stiffness / oxidative stress / inflammation primary endpoints NS, cited for safety-tolerability reference in §6 and negative-evidence transparency in §4.6

PMID accounting. The 38 numbered entries above correspond to 32 unique PubMed-indexed PMIDs plus 3 PMC-only references (entries 12 / 15 / 32, DOIs are stable and PMC mirrors are live) plus 2 negative-evidence references cited for §4.6 transparency. One additional historical PMID remains flagged for D8 NCBI esummary API re-verification and is not included in this v2 evidence table to avoid unverified-citation risk.

Regulatory References (not counted in PMID total)

← All Ingredients